PROTON THERAPY
THE UP-AND-COMING MARKET!
The Corporate Strategic Intelligence you need!
The World’s first
Proton Therapy
Market Report !
THE GLOBAL PROTON THERAPY MARKET WILL REACH
US$ 2.2 BILLION IN 2032, GROWING BY 9% ANNUALLY.
Today there are 39 proton therapy facilities for a total of 106 treatment rooms treating
patients around the world, representing merely 0.8% of all conventional radiotherapy
systems. By 2017 there will be 255 operational proton therapy treatment rooms.
Proton therapy remains a niche market however it is just up-and-coming and growing fast. It
has been subject to substantial interest in the past decade and significant growth in proton
treatment facilities around the world is expected in the foreseeable future. In 2011, the global
proton therapy devices market reached US$ 350 million. We project the global addressable
market at 1,000 particle therapy treatment rooms, valued at US$ 2.2 billion (including
services) by 2032, showing an average annual growth of 9% from 2011 to 2032.
IBA clearly dominated the world market for the past 20 years. However for several years,
other vendors, such as Varian, have been increasing their market share. For the year 2017,
we estimate that IBA will hold just over 30% of the world particle therapy market, followed by
Varian with 15% and by Mitsubishi and Hitachi holding a 9% market share each. The three
Japanese particle therapy manufacturers, while mostly active in Japan for the past two
decades, are now developing their strategies to be more active worldwide.
The primary purpose of this proton therapy MarketRTM report is to provide a comprehensive
review of the market situation and analyze trends to the year 2032. In particular, this report
provides you with an insight on the proton therapy global market, including:







Market size and shares;
Future trends and potential to 2032;
Maps and list of all operational PT facilities;
Maps and list of future PT centers to 2017;
Investments involved in a PT center;
Profile of PT competitors;
As well as carbon therapy.
The Proton Therapy Global MarketRTM report may prove valuable for industry insiders,
finance professionals (analysts, investors), media, as well as potential new proton therapy
centers, etc…
The report has been prepared by Paul-Emmanuel GOETHALS, MBA, Founder and
Management Consultant at CSIntell.
© 2012 – Proton Therapy MarketR
TM
– October 2012 – Page 2/5
Table of Contents
4
Introduction
Disclaimer
6
Methodology
7
Executive Summary
8
Overview
10
Health Information
General
Cancer data
Radiotherapy equipment in the world
12
13
15
18
Current Market
Overview
Operational Particle Therapy sites
Operational PT sites: Competitors
21
22
23
31
Market – Next Five Years
The World Market in 2017
The World Market in 2017: Competitors
USA in 2017
Europe in 2017
Asia in 2017
Japan in 2017
Rest of the World in 2017
34
35
43
45
47
49
51
53
Global Perspective 2032
Overview
Perspective in Treatment Rooms
Perspective in Value (US$)
55
56
58
65
Patient Statistics
Evolution of Patients Treated with PT
Patients Treated by Equipment Providers
Global Cost of PT treatment
71
72
75
76
Economics of Proton Therapy
Overview
Proton Therapy Investment
Proton Therapy Revenue Potential
77
78
79
81
© 2012 – Proton Therapy MarketR
TM
– October 2012 – Page 3/5
Table of Contents
Reimbursement
Overview
The US Case
The Case of France
82
83
85
88
Industry Players
Promoters of Proton Therapy
89
90
Competitors
Overview
Equipment Provided
SWOT
Revenues 2010 - 2014
Hitachi
IBA
Mevion Medical Systems
Mitsubishi
Optivus Proton Therapy
ProTom
Siemens
Sumitomo
Varian Medical Systems
CPAC (Compact Particle Acceleration Corporation)
92
93
94
95
97
99
102
106
110
113
115
117
118
122
126
Appendix
Appendix A (list of active PT sites as of September 2012)
Appendix B (list of PT facilities under construction or project close
to start)
Appendix C (list of PT facilities sorted by vendor)
Appendix D (list of PT facilities and their websites)
128
129
Total number of pages: 144
© 2012 – Proton Therapy MarketR
TM
– October 2012 – Page 4/5
131
134
139
How to Order
& Contact
For more information please send an e-mail with your contact
details to [email protected]
About CSIntell
CSIntell provides the Corporate Strategic Intelligence you need!
Paul-Emmanuel Goethals founded CSIntell as a new approach to connect Strategic
Information needed by Senior Executives to business needs, in a concise and
understandable way.
Paul-Emmanuel has 23 years of experience in consulting, business development,
intelligence and investors relations with a unique understanding of the medical and
healthcare markets.
Most recently he was Vice President Business Development & Capital Markets and
Special Counsel to the CEO at Eckert & Ziegler Group and he was Director Corporate
Business Development & Investor Relations at IBA for 11 years.
Please visit us at: www.csintell.com
Contact
CSIntell
Paul-Emmanuel GOETHALS, MBA
Founder, Management Consultant
Mobile: +32 491 080 968
E-mail:
[email protected]
© 2012 – Proton Therapy MarketR
TM
– October 2012 – Page 5/5
Download

PROTON THERAPY